RxDoctor Payments Data

Nathaniel Sann

Family · Windber, PANPI 1568692549

Payments from drug & device makers

$1,433in general payments, 2019–2025

Across 22 payments — averaging $65.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$577
  • Medical Device Business Services, Inc.$438
  • Reshape Lifesciences Inc.$223
  • Novo Nordisk$111
  • Teleflex LLC$46
  • Apollo Endosurgery US Inc$22
  • plus $16 from 1 others

What the payments were for

  • Consulting fees$41029%
  • Travel & lodging$302%
  • Food & beverage$96067%
  • Entertainment$332%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic5$577
Medical Device Business Services, Inc.2$438
Reshape Lifesciences Inc.6$223
Novo Nordisk6$111
Teleflex LLC1$46
Apollo Endosurgery US Inc1$22
Lilly USA, LLC1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,433 in reported general payments places this provider in the 75th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$10,214
Medicare patients
65
Services billed
141

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Omeprazole59$476
Ondansetron OdtOndansetron18$396
Famotidine19$251
Pantoprazole Sodium17$135

Paid to pharmacies, not to this prescriber.

Other family in Windber

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →